Commentary from EB McLindon on the challenges of patient recruitment and the need for current recruitment methods to evolve, especially for trials involving rare diseases and oncology.
Commentary from EB McLindon on the challenges of patient recruitment and the need for current recruitment methods to evolve, especially for trials involving rare diseases and oncology.